Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2017-11-03 16:34:05
Reporting Period:
Accepted Time:
2017-11-03 16:34:05
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1501989 Cytomx Therapeutics Inc. CTMX Pharmaceutical Preparations (2834) 273521219
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1654058 A. Sean Mccarthy 151 Oyster Point Blvd.
Suite 400
South San Francisco CA 94080
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-01 14,342 $0.95 18,587 No 4 M Direct
Common Stock Disposition 2017-11-01 14,342 $19.86 4,245 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2017-11-01 14,342 $0.00 14,342 $0.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
119,293 2023-02-25 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 158,737 Indirect See footnote
  1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.61 to $20.22, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees.
  4. 100% of the shares subject to the option are fully vested and exercisable.